<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854228</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0506</org_study_id>
    <nct_id>NCT02854228</nct_id>
  </id_info>
  <brief_title>PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon</brief_title>
  <acronym>PITUICARE-Lyon</acronym>
  <official_title>PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe predictors of pituitary tumor recurrence and markers
      of persistent disease activity through computerized collection of comprehensive demographic,
      therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions
      of all types.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS)</measure>
    <time_frame>up to 10 years (postoperatively)</time_frame>
    <description>Clinical, biochemical et imaging evaluation of a cohort of patient operated in the referral center for pituitary tumor.
Identification of recurrence or progression an analysis of the clinicopathological classification.
Evaluation of the different therapeutic strategies (med, surgery, chemotherapies, radiation therapy) to prevent recurrence or tumor progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy.</measure>
    <time_frame>2007-2020</time_frame>
    <description>Analysis of the expression of SST receptors in GH, PRL and ACTH secreting pituitary tumors: SSTR expression accessed by immunohistochemistry of the pituitary tumor.
Evaluation of the response to somatostatine analogs: somatostatine analogs efficacy evaluated by normalization of hormone hypersecretion in ACTH, GH and PRL secreting pituitary tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide.</measure>
    <time_frame>2007-2020</time_frame>
    <description>Evaluation of MGMT expression (accessed by immunohistochemistry of the pituitary tumor) and response to temozolomide treatment (evaluated according to RECIST criteria) for patient presenting multirecurrent tumors resistant to conventional treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Pituitary Tumor</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and pituitary tumor frozen sample (Neurobiotec Biological Resource Centre (BRC) of
      Hospices Civils de Lyon (HCL))
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        tertiary referral center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • patients with confirmed pituitary disease

        Exclusion Criteria:

        • patients who do not have confirmed pituitary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Raverot, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerald Raverot, MD PhD</last_name>
    <phone>(0)472119325</phone>
    <phone_ext>+33</phone_ext>
    <email>gerald.raverot@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel Jouanneau, MD PhD</last_name>
    <phone>(0)472357411</phone>
    <phone_ext>+33</phone_ext>
    <email>emmanuel.jouanneau@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupement Hospitalier Est, Lyon, France</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Raverot, MD PhD</last_name>
      <phone>(0)472119325</phone>
      <phone_ext>+33</phone_ext>
      <email>gerald.raverot@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel Jouanneau, MD PhD</last_name>
      <phone>(0)472357411</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuel.jouanneau@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pituitary tumor</keyword>
  <keyword>pituitary carcinoma</keyword>
  <keyword>acromegaly</keyword>
  <keyword>cushing</keyword>
  <keyword>prolactinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

